Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 12 2021
28 12 2021
Historique:
received:
18
05
2021
accepted:
03
08
2021
pubmed:
29
9
2021
medline:
8
1
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
Rare hematologic malignancies display evidence of both myeloid and lymphoid differentiation. Here, we describe such a novel bilineal event discovered in an adult woman with B-lymphoblastic leukemia (BLL). At the time of BLL diagnosis, the patient had a normal karyotype and a bulk sequencing panel identified pathogenic variants in BCOR, EZH2, RUNX1, and U2AF1, a genotype more typical of myeloid neoplasia. Additionally, the patient was noted to have 3-year history of cytopenias, and morphologic dyspoiesis was noted on post-treatment samples, raising the possibility of an antecedent hematologic disorder. To investigate the clonal architecture of her disease, we performed targeted sequencing on fractionated samples enriched for either B-lymphoblasts or circulating granulocytes. These studies revealed a truncal founder mutation in the spliceosome gene U2AF1 in both fractions, while distinct secondary mutations were present only in B-lymphoblasts (BCOR, NRAS) or myeloid cells (ASXL1, EZH2, RUNX1). These results indicate that both processes evolved from a common U2AF1-mutated precursor, which then acquired additional mutations during a process of divergent evolution and bilineal differentiation. Our findings highlight an atypical mechanism of BLL leukemogenesis and demonstrate the potential utility of fractionated sequencing in the characterization of acute leukemia.
Identifiants
pubmed: 34581783
pii: 477048
doi: 10.1182/bloodadvances.2021005308
pmc: PMC8714722
doi:
Substances chimiques
Splicing Factor U2AF
0
U2AF1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5612-5616Subventions
Organisme : NCI NIH HHS
ID : K12 CA120780
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Oncotarget. 2016 Oct 4;7(40):65485-65503
pubmed: 27602765
Leukemia. 1995 Oct;9(10):1783-6
pubmed: 7564526
Pathobiology. 2007;74(2):115-20
pubmed: 17587882
Mod Pathol. 1998 Dec;11(12):1211-21
pubmed: 9872654
Blood Adv. 2019 Dec 23;3(24):4228-4237
pubmed: 31869410
Blood. 2016 Nov 3;128(18):2263-2266
pubmed: 27625363
Nat Commun. 2019 Jun 21;10(1):2750
pubmed: 31227714
Blood. 2017 Jun 22;129(25):3371-3378
pubmed: 28424163
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Br J Haematol. 1986 Nov;64(3):487-91
pubmed: 3539173
Blood. 2015 Nov 19;126(21):2355-61
pubmed: 26429975
Br J Haematol. 1998 Jan;100(1):123-8
pubmed: 9450800
Oncol Lett. 2018 Jun;15(6):9745-9750
pubmed: 29805685
Leuk Res. 2006 Feb;30(2):233-9
pubmed: 16046234